-
Je něco špatně v tomto záznamu ?
Understanding the Patient Perception of Statin Experience: A Qualitative Study
M. Vrablik, AL. Catapano, O. Wiklund, Y. Qian, P. Rane, A. Grove, ML. Martin,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
Not applicable
Amgen - International
- MeSH
- anticholesteremika škodlivé účinky terapeutické užití MeSH
- bolest chemicky indukované MeSH
- dospělí MeSH
- dyslipidemie farmakoterapie epidemiologie MeSH
- kvalitativní výzkum MeSH
- lidé středního věku MeSH
- lidé MeSH
- průzkumy a dotazníky MeSH
- senioři MeSH
- spokojenost pacientů statistika a číselné údaje MeSH
- statiny škodlivé účinky terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
INTRODUCTION: Statin intolerance (SI) occurs in patients with dyslipidemia treated with statins. Statin-associated symptoms have been reported, but the overall patient experience is poorly understood. No instruments are available to collect this patient experience. Our aim is to develop a patient survey to define SI from the patient's perspective, inform clinical practice, and identify potential patient characteristics and barriers associated with discontinuing treatment when statin-related difficulties are encountered. METHODS: We conducted qualitative concept elicitation interviews with 65 patients across 12 European study sites. A semi-structured qualitative interview guide was developed based on literature review and clinician interviews. Concept elicitation interviews with patients were used to describe the patient experience and develop the conceptual framework for the survey. RESULTS: Symptoms experienced by patients included muscle and non-muscle-related pain and discomfort; other muscle-related symptoms; gastrointestinal, cardiovascular, cold-like, fatigue-related, and sensory and systems symptoms; mood changes; and cognitive and memory problems. Impacts included limitations on general physical functioning; physical activities; social functioning; emotional impacts; sleep disturbances; decreased productivity; and increased healthcare use. Conceptual framework elements to support survey goals include demographic and clinical characteristics, health information and beliefs, statin side-effect history, symptom severity, and impact severity. CONCLUSIONS: Symptoms and impacts described by patients showed a wider range of symptoms and impacts than usually discussed clinically. The patient survey is designed to capture information from patients who experience difficulties with statin therapy and may be useful in identifying patients who are at higher risk for giving up or discontinuing their treatment. FUNDING: Amgen Inc.
Amgen Inc One Amgen Center Drive Thousand Oaks CA USA
Charles University and General University Hospital of Prague Prague Czech Republic
Health Research Associates Inc 6505 216th St SW Suite 105 Mountlake Terrace WA 98043 USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023600
- 003
- CZ-PrNML
- 005
- 20201214130533.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12325-019-01073-7 $2 doi
- 035 __
- $a (PubMed)31482507
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vrablik, Michal $u Charles University and General University Hospital of Prague, Prague, Czech Republic.
- 245 10
- $a Understanding the Patient Perception of Statin Experience: A Qualitative Study / $c M. Vrablik, AL. Catapano, O. Wiklund, Y. Qian, P. Rane, A. Grove, ML. Martin,
- 520 9_
- $a INTRODUCTION: Statin intolerance (SI) occurs in patients with dyslipidemia treated with statins. Statin-associated symptoms have been reported, but the overall patient experience is poorly understood. No instruments are available to collect this patient experience. Our aim is to develop a patient survey to define SI from the patient's perspective, inform clinical practice, and identify potential patient characteristics and barriers associated with discontinuing treatment when statin-related difficulties are encountered. METHODS: We conducted qualitative concept elicitation interviews with 65 patients across 12 European study sites. A semi-structured qualitative interview guide was developed based on literature review and clinician interviews. Concept elicitation interviews with patients were used to describe the patient experience and develop the conceptual framework for the survey. RESULTS: Symptoms experienced by patients included muscle and non-muscle-related pain and discomfort; other muscle-related symptoms; gastrointestinal, cardiovascular, cold-like, fatigue-related, and sensory and systems symptoms; mood changes; and cognitive and memory problems. Impacts included limitations on general physical functioning; physical activities; social functioning; emotional impacts; sleep disturbances; decreased productivity; and increased healthcare use. Conceptual framework elements to support survey goals include demographic and clinical characteristics, health information and beliefs, statin side-effect history, symptom severity, and impact severity. CONCLUSIONS: Symptoms and impacts described by patients showed a wider range of symptoms and impacts than usually discussed clinically. The patient survey is designed to capture information from patients who experience difficulties with statin therapy and may be useful in identifying patients who are at higher risk for giving up or discontinuing their treatment. FUNDING: Amgen Inc.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a anticholesteremika $x škodlivé účinky $x terapeutické užití $7 D000924
- 650 _2
- $a dyslipidemie $x farmakoterapie $x epidemiologie $7 D050171
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x škodlivé účinky $x terapeutické užití $7 D019161
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a bolest $x chemicky indukované $7 D010146
- 650 _2
- $a spokojenost pacientů $x statistika a číselné údaje $7 D017060
- 650 _2
- $a kvalitativní výzkum $7 D036301
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Catapano, Alberico L $u University of Milan and Multimedica IRCCS, Milan, Italy.
- 700 1_
- $a Wiklund, Olov $u University of Gothenburg, Gothenburg, Sweden.
- 700 1_
- $a Qian, Yi $u Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.
- 700 1_
- $a Rane, Pratik $u Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.
- 700 1_
- $a Grove, Alyson $u RoundPeg Research, Oxford, UK.
- 700 1_
- $a Martin, Mona L $u Health Research Associates, Inc., 6505 216th St. SW, Suite 105, Mountlake Terrace, WA, 98043, USA. mona.martin@evidera.com.
- 773 0_
- $w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 36, č. 10 (2019), s. 2723-2743
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31482507 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130532 $b ABA008
- 999 __
- $a ok $b bmc $g 1595919 $s 1114276
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 36 $c 10 $d 2723-2743 $e 20190903 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
- GRA __
- $a Not applicable $p Amgen $2 International
- LZP __
- $a Pubmed-20201125
